Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRGX CARGO Therapeutics	$4.46 -0.4%	$4.45	$3.00 ▼ $25.45	$215.69M	0.3	1.20 million shs	1.81 million shs
ETST Earth Science Tech	$0.19 -0.1%	$0.17	$0.00 ▼ $0.25	$55.89M	1.95	104,613 shs	80,188 shs
LCTX Lineage Cell Therapeutics	$1.01	$0.94	$0.37 ▼ $1.21	$230.64M	1.66	1.90 million shs	1.16 million shs
TVRD Tvardi Therapeutics	$23.60 -2.2%	$25.07	$8.13 ▼ $34.31	$220.90M	0.21	34,226 shs	22,159 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRGX CARGO Therapeutics	-0.22%	0.00%	-2.40%	+12.85%	-67.93%
ETST Earth Science Tech	-2.56%	+2.54%	-5.00%	+31.49%	+15.29%
LCTX Lineage Cell Therapeutics	+2.60%	+4.12%	-1.94%	+114.89%	+11.89%
TVRD Tvardi Therapeutics	+0.88%	-8.39%	-11.74%	+2,412,999,900.00%	+2,412,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRGX CARGO Therapeutics	2.4733 of 5 stars	2.9	0.0	0.0	0.0	3.3	1.7	1.3
ETST Earth Science Tech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LCTX Lineage Cell Therapeutics	2.2807 of 5 stars	3.5	0.0	0.0	0.0	2.3	3.3	0.6
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRGX CARGO Therapeutics	1.86	Reduce	$15.40	245.29% Upside
ETST Earth Science Tech	0.00	N/A	N/A	N/A
LCTX Lineage Cell Therapeutics	3.00	Buy	$4.20	315.84% Upside
TVRD Tvardi Therapeutics	3.00	Buy	$64.25	172.25% Upside

Current Analyst Ratings Breakdown

Latest ETST, LCTX, CRGX, and TVRD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2025	LCTX Lineage Cell Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$2.00
7/14/2025	TVRD Tvardi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$62.00
7/11/2025	TVRD Tvardi Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$52.00
7/8/2025	CRGX CARGO Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$3.70 ➝ $5.00
6/23/2025	LCTX Lineage Cell Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$2.00
6/23/2025	LCTX Lineage Cell Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/12/2025	TVRD Tvardi Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$78.00
5/21/2025	TVRD Tvardi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$7.83 per share	N/A
ETST Earth Science Tech	$33.12M	1.69	$0.01 per share	16.85	$0.01 per share	18.99
LCTX Lineage Cell Therapeutics	$9.50M	24.28	N/A	N/A	$0.35 per share	2.89
TVRD Tvardi Therapeutics	$7.14M	30.94	N/A	N/A	($3.02) per share	-7.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRGX CARGO Therapeutics	-$167.50M	-$4.64	N/A	N/A	N/A	N/A	-43.21%	-37.26%	N/A
ETST Earth Science Tech	$3.25M	N/A	0.00	∞	N/A	7.93%	76.74%	44.47%	N/A
LCTX Lineage Cell Therapeutics	-$18.61M	-$0.12	N/A	N/A	N/A	-169.57%	-22.64%	-15.27%	8/12/2025 (Estimated)
TVRD Tvardi Therapeutics	-$70.87M	N/A	0.00	∞	N/A	-595.39%	-710.04%	-79.00%	N/A

Latest ETST, LCTX, CRGX, and TVRD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	LCTX Lineage Cell Therapeutics	-$0.02	N/A	N/A	N/A	$1.47 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
ETST Earth Science Tech	N/A	N/A	N/A	N/A	N/A
LCTX Lineage Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRGX CARGO Therapeutics	N/A	12.37	12.37
ETST Earth Science Tech	0.01	0.99	0.83
LCTX Lineage Cell Therapeutics	N/A	3.82	3.82
TVRD Tvardi Therapeutics	N/A	32.48	31.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRGX CARGO Therapeutics	93.16%
ETST Earth Science Tech	N/A
LCTX Lineage Cell Therapeutics	62.47%
TVRD Tvardi Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
CRGX CARGO Therapeutics	2.92%
ETST Earth Science Tech	24.90%
LCTX Lineage Cell Therapeutics	26.80%
TVRD Tvardi Therapeutics	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRGX CARGO Therapeutics	116	48.36 million	46.95 million	N/A
ETST Earth Science Tech	3	294.30 million	221.02 million	Not Optionable
LCTX Lineage Cell Therapeutics	60	228.36 million	167.16 million	Not Optionable
TVRD Tvardi Therapeutics	80	9.36 million	9.07 million	N/A

ETST, LCTX, CRGX, and TVRD Headlines

Recent News About These Companies

Raymond James Initiates Coverage of Tvardi Therapeutics (TVRD) with Outperform Recommendation

July 15, 2025 | msn.com

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

July 15, 2025 | finance.yahoo.com

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

July 15, 2025 | businesswire.com

Tvardi Therapeutics (NASDAQ:TVRD) Earns Outperform Rating from Analysts at Raymond James Financial

July 14, 2025 | marketbeat.com

Equities Analysts Offer Predictions for TVRD FY2025 Earnings

July 14, 2025 | marketbeat.com

Cantor Fitzgerald Initiates Coverage of Tvardi Therapeutics (TVRD) with Overweight Recommendation

July 12, 2025 | msn.com

Tvardi Therapeutics Inc News (TVRD) - Investing.com

June 27, 2025 | investing.com

TVRD Tvardi Therapeutics, Inc.

June 19, 2025 | seekingalpha.com

Piper Sandler initiates Tvardi Therapeutics stock with overweight rating

June 13, 2025 | uk.investing.com

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

June 12, 2025 | benzinga.com

Tvardi Therapeutics Inc (TVRD)

June 7, 2025 | investing.com

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

May 27, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETST, LCTX, CRGX, and TVRD Company Descriptions

CARGO Therapeutics NASDAQ:CRGX

$4.46 -0.02 (-0.45%)

Closing price 04:00 PM Eastern

Extended Trading

$4.46 0.00 (-0.11%)

As of 04:39 PM Eastern

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Earth Science Tech OTCMKTS:ETST

$0.19 0.00 (-0.05%)

As of 03:49 PM Eastern

Earth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

$1.01 0.00 (0.00%)

Closing price 04:10 PM Eastern

Extended Trading

$0.99 -0.02 (-1.98%)

As of 07:56 PM Eastern

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Tvardi Therapeutics NASDAQ:TVRD

$23.60 -0.53 (-2.20%)

As of 04:00 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time